JS-K, a Nitric Oxide Prodrug, Has Enhanced Cytotoxicity in Colon Cancer Cells with Knockdown of Thioredoxin Reductase 1 by Edes, Kornelia et al.
JS-K, a Nitric Oxide Prodrug, Has Enhanced Cytotoxicity
in Colon Cancer Cells with Knockdown of Thioredoxin
Reductase 1
Kornelia Edes
1, Pamela Cassidy
1,2,5, Paul J. Shami
3, Philip J. Moos
4*
1Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States of America, 2Department of Dermatology, University of Utah, Salt Lake City, Utah,
United States of America, 3Department of Medicinal Oncology, University of Utah, Salt Lake City, Utah, United States of America, 4Department of Pharmacology and
Toxicology, University of Utah, Salt Lake City, Utah, United States of America, 5Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah, United States
of America
Abstract
Background: The selenoenzyme thioredoxin reductase 1 has a complex role relating to cell growth. It is induced as a
component of the cellular response to potentially mutagenic oxidants, but also appears to provide growth advantages to
transformed cells by inhibiting apoptosis. In addition, selenocysteine-deficient or alkylated forms of thioredoxin reductase 1
have also demonstrated oxidative, pro-apoptotic activity. Therefore, a greater understanding of the role of thioredoxin
reductase in redox initiated apoptotic processes is warranted.
Methodology: The role of thioredoxin reductase 1 in RKO cells was evaluated by attenuating endogenous thioredoxin
reductase 1 expression with siRNA and then either inducing a selenium-deficient thioredoxin reductase or treatment with
distinct redox challenges including, hydrogen peroxide, an oxidized lipid, 4-hydroxy-2-nonenol, and a nitric oxide donating
prodrug. Thioredoxin redox status, cellular viability, and effector caspase activity were measured.
Conclusions/Significance: In cells with attenuated endogenous thioredoxin reductase 1, a stably integrated selenocysteine-
deficient form of the enzyme was induced but did not alter either the thioredoxin redox status or the cellular growth
kinetics. The oxidized lipid and the nitric oxide donor demonstrated enhanced cytotoxicity when thioredoxin reductase 1
was knocked-down; however, the effect was more pronounced with the nitric oxide prodrug. These results are consistent
with the hypothesis that attenuation of the thioredoxin-system can promote apoptosis in a nitric oxide-dependent manner.
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Introduction
The mammalian thioredoxin system consists of the selenopro-
tein thioredoxin reductase (TR), thioredoxin (Trx), and electron
donor NADPH. The TR-Trx system participates in diverse redox
reactions in cells [1], from supporting DNA synthesis [2] to redox-
dependent cell signaling pathways [3–6]. Trx and TR may
facilitate growth and/or survival of malignant cells as their
expression is elevated in some tumors [7,8]. Thioredoxin reductase
enzymatic activity is not limited to thioredoxin, instead, many
substrates have been identified, including; selenocompounds,
ascorbate, lipoate, and oxidized lipids [9–11]. However, some
oxidized lipids function to inhibit TR1 activity by reacting with the
nucleophilic C-terminus that includes the Sec residue [12–14].
The adjacent selenocysteine (Sec) and cysteine (Cys) residues in
the C-terminus of mammalian TRs are required for reductase
activity when Trx is the substrate; however, Sec-deficient TR1
may have biochemical [15] and biological [16] activities distinct
from Sec-sufficient TR1 that may be relevant in cancer or other
disease. Sec-deficient TR1 has demonstrated pro-apoptotic
activity in studies evaluating the role of TR1 in interferon and
retinoic acid-induced apoptosis [17], as well as more recent
supporting data that has demonstrated Sec-deficient TR1 species
(designated SecTRAPs) are by themselves potent initiators of
apoptosis in human cancer cell lines [16]. Apoptosis in these cases
were hypothesized to be mediated by increased oxidative stress in
the cells. These examples suggest that disruption of the C-terminus
of TR1 results in a gain-of-function protein that might be a useful
pro-apoptotic agent if it could be targeted to malignant cells.
In this study we have examined the effects on colon cancer cells
of two scenarios in which canonical TR1 activity (i.e. the ability to
reduce Trx) has been mitigated either by siRNA treatment or
mutation of the C-terminal Sec and Cys residues. We began by
evaluating the redox status of Trx in RKO colon cancer cells
where endogenous TR1 levels were attenuated with siRNA. In
these same cells deficient in wild-type TR1, we then induced the
expressed a Sec-deficient TR1 and found that this protein altered
neither the Trx redox status nor the cellular growth kinetics. Only
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find differences in TR1-comprimised cells. This led us to examine
the effects of TR1 knockdown on a variety of oxidative stressors
including reactive oxygen species, an electrophilic lipid and a nitric
oxide (NO)-prodrug. The effects of TR1 depletion were most
pronounced in combination with the latter treatment.
NO has a broad spectrum of physiological effects, including
pronounced effects in the vascular and nervous systems [18,19]. It
also is promising as an antineoplastic pharmacological agent due
to its cytotoxicity; however, optimal clinical response requires
novel delivery mechanisms of the NO to the tumor rather than
systemic administration to avoid the vascular adverse effects [20].
O
2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl) piperazin-1-yl]dia-
zen-1-ium-1,2-diolate (JS-K) is a prodrug designed to release
NO intracellularly [21] therefore avoiding generalized effects on
the vasculature. The release of NO from JS-K is dependent on
metabolism by glutathione S-transferases (GSTs) and this
dependency may provide additional neoplastic selectivity since
GSTs are frequently overexpressed in cancer [22]. JS-K has
demonstrated antineoplastic efficacy in both human cancer cell
lines as well as animal model systems [23].
NO can have diverse effects in cells. Functioning as an oxidant,
it can react with metal ions, or directly modify proteins on cysteine
residues forming S-nitrosothiols. This modification can modulate
protein function [24]. The cellular redox management of cysteine
nitrosylation is an active area of research, and the TR-Trx system
has been identified as a regulator of this phenomenon [25]. In
particular, apoptotic proteins have been identified as target
proteins modified by nitrosylation [26]. Indeed, the effector
caspase, caspase-3, is target of nitrosylation that is modulated by
cytosolic and mitochondrial Trx systems [27]. Therefore, NO and
the TR-Trx system are integral components in cellular processes
of programmed cell death. In the current work we extend the
study of this interaction to include the effects of TR1 on the
activity of an important new candidate cancer therapeutic agent,
JS-K.
Results
Mammalian thioredoxin reductase without a Sec was thought
to have minimal activity; however, recent reports suggest that
Sec-deficient thioredoxin reductase might have other redox
activities. Therefore, we constructed an inducible cell line where
we could express a C-terminal mutant of TR1 that was resistant
to siRNA knockdown. We measured the expression of TR1 by
Western blotting and measured the TR activity based on insulin
reduction as well as lipoic acid reduction (Figure 1). The siRNA
effectively knock down the endogenous TR1 by ,70% and the
tetracycline induction of the stably integrated of the C-terminal
mutant was ,75% of the level of the endogenous TR1
(Figure 1A). In addition, the knockdown resulted in ,70%
reduction of TR activity as measured by the biochemical assay of
NADPH oxidation with Trx as the intermediate and insulin
serving at the final electron acceptor (Figure 1B). Since TR1 can
reduce alternative substrates to Trx in vitro, we also evaluated the
ability of the C-terminal mutant of TR1 to reduce lipoic acid in a
cell based assay (Figure 1C). Several cellular enzymes can reduce
lipoate but we did observe an ,40% diminution of lipoate
reduction in the RKO cells with endogenous TR1 attenuated by
the siRNA and in the cells expressing the C-terminal mutant
TR1.
Since Trx is a primary substrate of TR1 and since other Sec-
deficient TR1 have demonstrated oxidative stress, we measured
the Trx redox status to determine if the Sec-deficient C-terminal
Figure 1. Characterization of TR1 levels and activity in RKO
cells. Cells were exposed to siRNA directed against TR1 for a total of
96 hrs, and a Sec-deficient C-terminal mutant TR1 was induced for
the last 24 hrs. A) Immunoblot analysis of TR1 protein expression
following siRNA treatments and induction of the Sec-deficient
mutant TR1. B) TR biochemical activity measured in cell lysates by
monitoring NADPH oxidation in an assay that is dependent on Trx
and uses insulin is the final electron acceptor. The first bar on the left
represent the activity of the control (si-Scramble) without Trx added
to the reaction mix, indicating background signal. C) Cell-based TR
activity as measured by lipoic acid reduction in a colorimetric assay
using Ellman’s reagent. The first bar on the left represent the activity
of the control (si-Scramble) without lipoic acid added to the reaction
mix. The lysates from cells with TR1 knocked down show significant
reductions in activity compared to the control (si-Scramble) in both
assays (***, p,0.001).
doi:10.1371/journal.pone.0008786.g001
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redox status was performed through alkylation with iodoacetic
acid, reduction of oxidizedC y sw i t hD T T ,a n dt h e n
iodoacetamide alkylation, as has been described [28]. No
changes in Trx redox status were observed among the cells
with endogenous TR1, cells with TR1 knocked-down, and cells
with endogenous TR1 knocked-down plus induction of the Sec-
deficient C-terminal mutant TR1 (example dataset in Figure 2
and summary of multiple experiments in Table 1). If the cells
were challenged with 1 mM diamide, changes in the redox
status of Trx were observed, and a difference between the si-
TR1 treated cells and the si-Scramble was evident suggesting
that the assay detects alterations in redox status following an
oxidative challenge.
Since Sec-deficient TR1 has demonstrated enhanced cytotoxicity
in other systems and so one possibility was that the cells with the
inducible Sec-deficient TR1 are not proliferating at a similar rate as
cells with endogenous TR1. We measured the rate of cell growth
following siRNA knockdown and induction of expression the Sec
deficient TR1 by counting cell population numbers (Figure 3). The
cellular doubling time for all three conditions was ,24 hrs,
following an initial lag period. Therefore, this Sec-deficient TR1
mutant did not appear to alter the growth kinetics of the RKO cells
as no significant differences in the slopes of the growth curves were
measured (0.3560.004 cells/hr for si-Scramble, 0.3660.006 cells/
hr forsi-TR1,and 0.3360.008 cells/hr forsi-TR1plusinductionof
the C-terminal mutant TR1).
Since the induced expression of the Sec-deficient C-terminal
mutant TR1 construct did not elicit an alteration in redox status of
Trx, we evaluated the cytotoxic response of RKO cells with
endogenous TR1 as well as cells where the TR1 was attenuated
with siRNA to reactive oxygen and nitrogen in the form of H2O2,
the oxidized lipid 4-HNE, or the NO donor JS-K (Figure 4).
Viability following H2O2 exposure was not different (Figure 4A);
the 4-HNE exposure demonstrated a modest, ,2-fold increased
sensitivity in the cells with TR1 knocked-down with a LC50
difference of 10.660.7 mM in the cells with TR1 knocked down
compared to 2463.4 mM in the cells with endogenous TR1
(Figure 4B); the NO donor, JS-K, demonstrated ,6-fold increased
sensitivity in the cells with TR1 attenuated by siRNA with a LC50
difference of 3.160.5 mM in the cells with TR1 knocked down
compared to 1962 mM in the cells with endogenous TR1, as
measured with a MTT assay (Figure 4C).
Since the NO-donor promoted a more prominent difference in
viability between the RKO cells with endogenous TR1 compared
to the cells with TR1 knocked-down, additional evaluation of
cellular redox status were performed to evaluate the mechanism
of the NO-mediated enhanced cytotoxicity. First, based on the
significant differences in cell viability observed in the MTT assay,
the Trx redox status was evaluated following 5 mMJ S - K
incubation. The JS-K treated TR1 knockdown cells displayed a
more oxidized distribution of Trx redox states following 90 min
incubation with the NO prodrug (Table 2). Next, a more
generalized evaluation of the oxidative state of the cells was
evaluated following 5 mM JS-K treatment for 24 hrs by
measuring the ratio of reduced GSH to the total GSH levels.
No significant differences in reduced GSH to total GSH were
observed (Figure 5). These data suggest that a global change in
redox status was not observed but that select proteins might be
targeted.
To determine the mechanism behind the changes in cellular
viability as determined by the MTT assay, immunoblot analysis of
Figure 2. Evaluation of the 6 possible redox states of Trx. In
cells without stimulation (left three lanes), Trx is primarily in the reduced
state, even with TR1 knocked-down and the C-terminal mutant TR1
expressed. With 1 mM diamide stimulation for 30 min (right three
lanes), cells with endogenous TR1 demonstrate more reduced Trx than
cells with endogenous TR1 knocked-down with siRNA.
doi:10.1371/journal.pone.0008786.g002
Table 1. Summary of Trx redox status following TR1 knockdown and Sec-deficient TR1 expression: Percent Trx in each redox state
(% total).
Redox state si-Scramble si-Scramble
+diamide
si-TR1 si-TR1
+diamide
si-TR1+mTR1 si-TR1+mTR1
+diamide
1 (oxidized) 0.760.2 2.961.7 1.660.4 5613 60.8 3.660.6
20 . 7 60.2 1163.2 1.960.6 2263.8 2.460.8 2464.4
31 . 9 60.4 1661.3 3.561.0 29647 60.7 3662.8
47 . 6 61.3 4266.1 8.761.1 3263.3 961.9 3464.4
51 7 61.9 1462.9 1662.4 960.2 860.7 661.9
6 (reduced) 7562.3 2164.6 6862.8 4.5627 6 63.2 4.361
Summary of the 6 possible redox states, from the most oxidized (state 1) to the least (state 6) of Trx in RKO cells with endogenous TR1 (si-Scramble), with endogenous
TR1 knocked-down (si-TR1), or endogenous TR1 knocked-down but with induced Sec-deficient mutated TR1 (si-TR1+mTR1). Since the majority of the Trx was found to
be in the reduced state, we stimulated with 1 mM diamide for 30 min to oxidize the cells and those cells without endogenous TR1 display more oxidized Trx than cells
with endogenous TR1.
doi:10.1371/journal.pone.0008786.t001
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polymerase (PARP) were evaluated (Figure 6). Cleaved caspase 3
is consistent with the initiation of apoptosis and the amount of
caspase 3 cleavage appeared to be more extensive when TR1 was
knocked-down. Cleaved PARP was also observed in these
experiments in a dose dependent manner.
Evidence of apoptosis initiation was observed at both 1.5 and
5 mM JS-K in the immunoblot analysis; therefore, the cellular
viability and cytotoxicity where re-evaluated following 1.5 mM JS-
K incubation (where the cells still appear .75% viable, Figure 4)
based on protease activity using the MultiTox assay. This assays
appeared to be more sensitive than the MTT assay, since even at
this low dose, JS-K resulted in significant cytotoxicity and/or loss
of viability in the TR1 knockdown cells (,45% viable) compared
to the cells with endogenous levels of TR1 (,68% viable,
Figure 7A and 7B). Next the relative caspase-3/7 activity was
measured and consistent with the cytotoxicity data, there was a
significant enhancement of caspase activity in the cells with TR1
knocked-down (Figure 7C). In separate experiments, the broad
spectrum competitive caspase inhibitor, Z-Asp-CH2-DCB, was
included during the incubation with JS-K confirming the
enzymatic activity previously observed was caspase-dependent
activity.
Discussion
While selenoprotein levels are generally dependent on selenium
and selenium deficiency appears to result in increased risk of
cancer mortality [29], the TR1-Trx system may be unusual among
selenoenzymes in its ability to promote cancer [8,30]. Indeed, Trx
is frequently over expressed in many tumors, may have anti-
apoptotic properties, and may contribute to some forms of therapy
resistance [7,31–34]. From this perspective, inhibition of TR1 is
an excellent target to inhibit the reduction of thioredoxin in the
presence of additional oxidative stress. Also, several commonly
used therapeutic agents, like cisplatin, cyclophosphamide, and
doxorubicin appear to target thioredoxin reductase as well as
Figure 3. Cell growth kinetics of RKO cells with modulated TR1
levels. A scrambled siRNA was used as a control to measure the basal
growth rate (filled square) TR1 was knocked-down by siRNA (filled
circle) and with induction of the Sec-deficient, C-terminal mutant TR1
(filled triangle). No significant differences in growth rates were observed
as the solid lines used to calculate the growth rates for these conditions
are nearly parallel.
doi:10.1371/journal.pone.0008786.g003
Figure 4. MTT-based viability assays for RKO cells following
increasing concentrations of redox modulators. Cells with
endogenous TR1 (si-Scramble, filled square), and cells with TR1
knocked-down by siRNA (si-TR1, filled circle) were compared at
equivalent doses of the redox modulators. A) RKO cells were treated
with increasing concentrations of H2O2 and the viability was measured
after a 24 hrs exposure. No significant differences were observed. B)
RKO cells were treated with increasing concentrations of 4-HNE and the
viability was measured after a 24 hrs exposure. The si-TR1 cells
displayed ,2-fold increased sensitivity to 4-HNE. C) RKO cells were
treated with increasing concentrations of JS-K and the viability was
measured after a 24 hrs exposure. The si-TR1 cells displayed ,6-fold
increased sensitivity to JS-K.
doi:10.1371/journal.pone.0008786.g004
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insufficient to alter the growth status of cells, but that appropriate
redox stress following attenuation of TR1 may be the most
effective means of attaining a cytotoxic response.
The antiapoptotic activity of Trx has been sited as rationale for
targeting the TR-Trx system in human cancer [40,41]. The recent
observation that the TR-Trx system modulates the activity of
caspase-3 in a nitrosylation-dependent manner [27] suggests a
prominent role for the TR-Trx system in NO-mediated apoptotic
activity. In this work, we also observe that the NO prodrug, JS-K,
increases apoptosis when TR1 is knocked down with siRNA
(Figures 4 and 6). This mechanism is consistent with previous
mechanistic data demonstrating increased caspase activity in acute
myelogenous leukemia cells [42]. In addition, NO-donating
aspirin demonstrated synergistic activity when combined with
gold-containing compounds that are thought to primarily target
the TR-Trx system [43].
The role of TR1 in apoptosis has been the subject of
investigation since it was identified as a ‘‘GRIM’’ gene (i.e.,
genes associated with retinoid-IFN-induced mortality, GRIM 12)
in a screen for genes related to retinoid-IFN-induced apoptosis
[17]. More recently, it has been demonstrated that TR1 protein
without a functional Sec residue due to alkylation or truncation,
when introduced to cells using BioPORTER, induced apoptosis
[16,44]. However, the mechanisms of TR-mediated apoptosis by
TR1 SecTRAPs remain unknown. The mutant TR1 we utilized,
with the C-terminus Gly-Ser-Ser-Gly, was not a functional
thioredoxin reductase as measured by NADPH oxidation/
insulin reduction as well as lipoic acid reduction (Figure 1);
however, it also did not appear to function as a SecTRAP
apoptotic initiator as described by Arne ´r and colleagues [16].
Similar to a previous report [45], we were unable to identify
basal alterations in Trx or cellular redox status when TR1 was
knocked-down with siRNA (Figure 2, Table 1) but did observe
altered Trx redox status following JS-K treatment (Table 2). In
addition, the expression of this Sec-deficient mutant TR1 did not
alter the oxidative status of Trx. Therefore, it appears that not
all Sec-deficient TR proteins promote oxidative stress and
apoptosis.
Targeting TR1 for cancer therapy may not be without
undesirable adverse effects if it is not targeted at the tumor. For
example, the tumor suppressor, p53, is an important regulator of
cell growth and apoptosis, and TR1 enhances p53 function,
presumably by contributing reducing equivalents through Trx to
the nuclear redox regulator Ref-1 [12,13,46,47]. Several common-
ly used therapeutic agents, like cisplatin, cyclophosphamide, and
doxorubicin appear to target TR1 as well as DNA [35-39], but
perhaps, a cause for some of the adverse effects observed with these
common therapeutics, may be the ‘‘off-target’’ inhibition of TR1.
Another redox modulatory compound that has been evaluated in
Figure 5. RKO cellular redox state following JS-K treatment as
measured by glutathione redox status. GSH measurements were
made following treatment with 5 mM JS-K for 24 hrs., and the ratio of
the reduced GSH to the total GSH was measured. No significant
differences were observed among the treatment groups.
doi:10.1371/journal.pone.0008786.g005
Table 2. Summary of Trx redox status following TR1
knockdown and JS-K treatment: Percent Trx in each redox
state (% total).
Redox state si-Scramble si-Scramble
+JS-K
si-TR1 si-TR1
+JS-K
1 (oxidized) 0.360.3 0.560.5 0.460.6 1.460.2
20 . 6 60.7 1.961.4 0.460.4 2.462.0
31 . 5 60.3 7.962.3 2.161.2 1561.8
46 . 4 61.3 1863.6 9.960.3 3261.1
51 9 61.8 3565.6 2362.8 2765.8
6 (reduced) 7263.8 38656 5 63.5 2465.4
Summary of the 6 possible redox states of Trx in RKO cells with endogenous
TR1 (si-Scramble) or with endogenous TR1 knocked-down (si-TR1) following
treatment with 5 mM JS-K for 90 min. Trx does show a shift to more oxidized
states in the cells treated with JS-K with TR1 knocked down.
doi:10.1371/journal.pone.0008786.t002
Figure 6. Immunoblot evaluation of cleaved PARP and caspase
3. RKO cells treated with vehicle, 1.5, or 5 mM JS-K for 24 hrs. Protein
was separated by SDS-PAGE and detected with immunoblot analysis. A
dose-dependent increase in cleaved PARP and caspase 3 (CASP3) was
observed with more cleaved material in the TR1 knockdown. GAPDH
was evaluated as a loading control.
doi:10.1371/journal.pone.0008786.g006
TR-Dependence of JS-K Toxicity
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specifically target TR1 [7]. However, motexafin gadolinium
appears to be a substrate for TR1 and generates reactive oxygen
species through this interaction as well as being an inhibitor of
ribonucleotide reductase [48]. If this compound’s clinical activity is
truly due to its interactions with TR1, it is still unclear which
tumors should be targeted since this compound has demonstrated
mixed results in clinical trials to date [49–51], but it appears to
hold particular promise as a radiation sensitizer [52,53].
Even with potential complications of targeting TR1 in cancers,
the results herein suggest that drug combination approaches, like
the NO-donor, JS-K, might be most effective if combined with
agents that target TR1.
Materials and Methods
Materials
Advanced DMEM, Glutamax, 5,59,6,69-tetrachloro-1,19,3,39-
tetraethylbenzimidazolyl-carbocyanine iodide (JC-1, MitoProbe
JC-1 Assay Kit), 3-(4,5-dimethylthiaxol-2-yl)-2,5-diphenyltretrax-
olium bromide (MTT), Hank’s balanced salt solution with Ca and
Mg (HBSS), Tris-glycine 8% gels and bovine serum albumin were
purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum
was purchased from Hyclone (Logan, UT). The RKO cell line was
purchased from American Tissue Type Culture Collection
(Manassas, VA). Monoclonal antibodies directed against thior-
edoxin reductase (B-2, sc-28321, lot# J1304); polyclonal antibod-
ies directed against thioredoxin (FL-105, sc-20146, lot# A1907),
and GAPDH (FL-335, sc-25778); donkey polyclonal anti-mouse
and anti-rabbit antibodies conjugated with horseradish peroxidase
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Additional polyclonal antibodies directed against caspase 3 (9661),
cleaved caspase 3 (9662), and PARP (9532) were purchased from
Cell Signaling Technology (Beverly, MA). Bovine serum albumin
standard and Coomassie Plus Protein Reagent were from Pierce
Biotechnology (Rockford, IL). Protease inhibitor cocktail tablets
(completeH) were purchased from Roche (Indianapolis, IN). PVDF
membrane was purchased from Millipore (Burlington, MA). The
caspase inhibitor, Z-Asp-CH2-DCB, was from Peptides Interna-
tional (Louisville, KY). Western Lighting chemiluminescence
reagents were from PerkinElmer Life Sciences (Boston, MA). JS-
K was synthesized as previously described [54]. Dimethylsulfoxide
(DMSO) and common buffers and salts were purchased from
Sigma-Aldrich (St. Louis, MO).
Cell culture
RKO colon cancer cells were used as a representative colon cell
line and were maintained in Advanced DMEM supplemented
with 1% Glutamax and 2% fetal bovine serum. Previously, we
described the site directed mutagenesis of the C-terminus of TR1
from Gly-Cys-Sec-Gly to Gly-Ser-Ser-Gly plus a silent mutation
into the siRNA identity site to make this construct resistant to
siRNA directed at the endogenous TR1. We subcloned this
mutated TR1 construct into pcDNA5/FRT/TO and then
inserted into the RKO cells with stably integrated pcDNA6/TR
and pFRT/lacZeo, rendering a tetracycline inducible mutant TR1
cell line. These mutations to TR1 as well as the siRNA used to
modulate endogenous TR1 were previously described [13].
Experimentally, the cells were plated at 2–3610
5 cells/well in 6
well plate and transfected with siRNA directed at TR1 (si-TR1) or
control generated by scrambling the si-TR1 sequence (si-
Scramble) for 72 hrs. Then, the cells were treated or stimulated
with tetracycline for 24 hrs as indicated.
Figure 7. Protease activity as a measure of viability, cytotoxity
and effector caspase activity. RKO cells treated with 1.5 mM JS-K for
24 hrs. were assessed for A) viability, B) cytotoxicity, and C) caspase-3/7
activity. In separate experiments, cells were incubated with Z-Asp-CH2-
DCB, a broad spectrum, competitive caspase inhibitor, to determine
that the caspase assay was indeed demonstrating effector caspase
activity (C). RKO cells with TR1 knocked-down demonstrate significantly
greater losses in viability, increased cytotoxicity, and increased caspase-
3/7 activity following JS-K treatment than RKO cells with endogenous
TR1 (**, p,0.01; ***, p,0.001; {{{,p ,0.001).
doi:10.1371/journal.pone.0008786.g007
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Cells in 6-well plates were placed on ice. Media was aspirated
and cells were then washed with 1 ml of cold 16PBS and the PBS
aspirated. Cell lysates were collected as previously described [13].
Protein concentrations were determined using Coomassie Plus
Protein Reagent (Pierce). Absorbance at 595 nm was measured
using a Perkin-Elmer Victor
3V plate reader. Ten to 15 mgo f
protein were separated on either 8% Tris-glycine gels (for TR1) or
10% native urea gels (for Trx), transferred to PVDF membrane,
blocked with 10% non-fat dry milk, incubated with primary
antibody (1:200 for TR, 1:250 for Trx, 1:1000 for both caspase 3
and cleaved caspase 3, 1:1000 for PARP, and 1:500 for GAPDH)
overnight at 4uC, washed 36, incubated with secondary antibody
(1:5000) for 45 min at 22uC, washed 36, incubated with
chemiluminesence reagents, and exposed to x-ray film.
Thioredoxin reductase activity assays
Cellular TrxR1 activity was measured as has been previously
described [13]. In addition, we measured lipoic acid reduction
similar to a previously described assay [55]. Briefly, cells were
plated and treated as described. Then the cells were trypsinized,
washed with PBS, and resuspended in a solution of 1 ml
containing 5 mM glucose in PBS, with or without 1 mM lipoic
acid and 0.2 mM DTNB with gently shaking at 37uC for 15 min.
The cells were centrifuged and the supernatant sample was diluted
1:1 with water and the absorbance was measured at 412 nm. The
negative control was medium with no cells. The cell pellet was
washed with PBS, lysed cells in lysis buffer and the protein
measured using the Bradford assay. The reduced lipoate was
normalized by the cellular protein content.
Redox status of Trx
The redox status of Trx was performed as described [28].
Briefly, cells were lysed in 8 M urea buffered with Tris to pH 8.9
containing 30 mM iodoacetic acid, sonicated, and incubated for
15 min at 37uC. Protein was precipated with 10 volumes of ice
cold acetone-1N HCl (98:2, vol/vol), centrifuged at 11,0006g for
5 min at 4uC, washed with cold acetone-HCl, resuspended in
95 ml of buffered urea containing 35 mM DTT, incubated for
30 min at 37uC, 7.5 ml of 200 mM iodoacetamide was add to each
sample, and incubated for 15 min at 37uC. Protein concentration
was estimated using Coomassie Plus Protein Reagent.
MTT assay
Cellular viability was determined using an MTT as previously
described [56], which relies on tetrazolium salt reduction by
NADH in viable cells (Berridge et al., 2005).
Glutathione quantitation
Reduced glutathione (GSH) and total GSH were measured
using GSH-GLO reagents (Promega). Approximately 2.5610
3
cells that were pre-incubated with siRNA directed at TR1 were
plated in white sided 384 well plates, allowed to adhere, and then
treated with 0 or 5 mM JS-K for 24 hrs. Media was removed by
centrifugation, the reduced GSH was directly measured according
to manufacturing instructions, and the total GSH was measured
by incubating the cells with 1 mM TCEP to reduce oxidized
GSH. This assay is a glutathione-S transferase-dependent assay
that uses GSH to generate luciferin as a substrate for luciferase to
generate light. Luminescence was measured using a Perkin-Elmer
Victor
3V plate reader.
MultiTox assay
Viability and cytotoxicity measurements were assessed by
differential protease activities using the MultiTox-Fluor Multiplex
Assay (Promega). This assay uses a GF-AFC substrate that is cell
permeable to assess the viable cells, and a bis-AAF-R110 substrate
that is not cell permeable to assess protease activity from dead
cells. The fluorescence from these substrates were measured using
a Perkin-Elmer Victor
3V plate reader; the GF-AFC viability
substrate was measured at 405 nm excitation, 475 nm emission;
and the bis-AAF-R110 cytotoxicity substrate was measured at
485 nm excitation, 535 nm emission.
Caspase activity assay
Effector caspase activity was measured using the Caspase-GLO
3/7 Assay (Promega) according to the manufacturer’s instructions.
This is an assay where a DEVD peptide substrate is cleaved by
active caspases to release aminoluciferin as a substrate for
luciferase to produce light. Luminescence was measured using a
Perkin-Elmer Victor
3V plate reader.
Statistical analysis
1-way ANOVA was used to determine statistical significance
among samples (GraphPad InStat Version 3.06). Bonferroni
multiple comparisons post hoc testing was used to establish
significance among the treatment groups with p,0.05 considered
significant.
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